The financials
Tandem Diabetes Care, Inc. by the numbers
Tandem Diabetes Care, Inc. (TNDM) reported revenue of $247M in Q1 2026 (quarter ended March 31, 2026), up 5.5% from the same quarter a year earlier. That came with a gross margin of 55% and net loss of $20M. For the full year FY2025, revenue was $1.01B (+7.9% year on year) and net income −$205M. Its largest product in 2026-Q1 was Supplies And Other at $137M, 55% of the disclosed total, just ahead of Pump at 45%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $247M | $234M | +5.5% |
| Gross profit | $137M | $118M | +16% |
| Operating income | −$17M | −$121M | n/a |
| Net income | −$20M | −$131M | n/a |
| Diluted EPS | −$0.30 | −$1.97 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Supplies And Other | $137M | 55% |
| Pump | $110M | 45% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $247.2M (-0.82%)
Pump grew +8.1% year on yearSupplies And Other +3.4% year on year
Segment Latestquarter on quarteryear on year
- Supplies And Other$136.8M$136.8MQoQ -1.7%year on year +3.4%-1.7%+3.4%
- Pump$110.4M$110.4MQoQ +0.26%year on year +8.1%+0.26%+8.1%
- Tandem Choice Program Recognized Deferred--QoQ -year on year ---